Extracorporeal hemocorrection in treatment of meningococcal septic shock in children

Cover Page

Abstract


Purpose: to estimate the effectiveness of extracorporeal hemocorrection in treatment of refractory meningococcal septic shock in children.

Methods: patients with generalized form of meningococcal infection, multi-organ system failure and refractory septic shock admitted to the resuscitation department of Children’s Clinical Research Center for Infectious Diseases of the Federal Medical and Biological Agency of Russia underwent extracorporeal hemocorrection (polymyxin adsorption, continuous veno-venous hemofiltration, continuous veno-venous hemodiafiltration). MultiFiltrate apparatus was used (Fresenius Medical Care, Germany).

Results: application of extracorporeal hemocorrection technique in the therapy of refractory meningococcal septic shock reduced the mortality from 44.4% to 25%.

Conclusion: effectiveness of extracorporeal hemocorrection when treating patients with refractory meningococcal septic shock is established. A small number of examined patients is a limitation of the study.


About the authors

Konstantin V. Serednyakov

Children’s Clinical Research Center for Infectious Diseases of the Federal Medical and Biological Agency of Russia

Author for correspondence.
Email: spbny@yahoo.com

Russian Federation

Head of ICU; Assistant of the Department of anesthesiology – resuscitation and emergency pediatrics of St. Petersburg pediatric medical University

Prof. Popov st. 9, St. Petersburg, Russia, 197022; phone: +7(911)134–11–21

Yuri V. Lobzin

Children’s Clinical Research Center for Infectious Diseases of the Federal Medical and Biological Agency of Russia

Email: niidi@niidi.ru

Russian Federation

Dr. Sci (Med), Professor, Director of “Children’s Clinical Research Center for Infectious Diseases of the Federal Medical and Biological Agency of Russia”; head of the Department of infectious diseases “North-Western state medical University named after I. I. Mechnikov”, honored scientist of the Russian Federation, General of medical service, academician of RAS

Prof. Popov st. 9, St. Petersburg, Russia, 197022

References

  1. Менингококковая инфекция и гнойные бактериальные менингиты в Российской Федерации. Информационно-аналитический обзор. Федеральное бюджетное учреждение науки «Центральный НИИ эпидемиологии» Роспотребнадзора РФ, 2016.
  2. Ishibe Y., Shibata S., Takahashi G., Suzuki Y., Inoue Y., Endo S. Association of type II secretory phospholipase A2 and surfactant protein D with the pulmonary oxygenation potential in patients with septic shock during polymyxin-B immobilized fiber-direct hemoperfusion. J. Clin. Apher. Oct 2017;32(5):302-10. doi: 10.1002/jca.21507. PMID: 27623356.
  3. Nishibori M., Takahashi H. K., Katayama H., Mori S., Saito S., Iwagaki H., Tanaka N., Morita K., Ohtsuka A. Specific removal of monocytes from peripheral blood of septic patients by polymyxin B-immobilized filter column. Acta Med. Okayama. 2009;(63):65-9. PMID: 19247424. doi: 10.18926/AMO/31855.
  4. Zagli G., Bonizzoli M., Spina R., Cianchi G., Pasquini A., Anichini V., Matano S., Tarantini F., Di Filippo A., Maggi E., Peris A. Effects of hemoperfusion with an immobilized polymyxin-B fiber column on cytokine plasma levels in patients with abdominal sepsis. Minerva Anestesiol. 2010;(76):405-12. PMID: 20473253.
  5. Kohro S., Imaizumi H., Yamakage M., Masuda Y., Namiki A., Asai Y., Maruyama I. Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J. Anesth. 2006;(20):11-6. PMID: 16421670. doi: 10.1007/s00540-005-0366-5.
  6. Tanaka Y., Okano K., Tsuchiya K., Yamamoto M., Nitta K.. Polymyxin B. Hemoperfusion improves hemodynamic status in patients with sepsis with both gram-negative and non-gram-negative bacteria. J. Clin. Exp. Nephrol., 2015;(1):4. doi: 10.21767/2472-5056.100004

Statistics

Views

Abstract - 167

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies